The potential of AI-powered drug discovery is huge.
This could lead to faster drug development, cheaper costs, and new cures.
40% off TNW Conference!
Last year, Isomorphic Labsinked a $45mndealwith Eli Lilly to collaborate on AI-based research into small molecule therapeutics.
Under the agreement, Isomorphic is also eligible to receive up to $1.7bn in performance-based milestones.
The company also signed a similarcollaborationwith Swiss biotech Novartis.
Were already working on real drug programs, Hassabis told Bloomberg Television in aninterviewshortly following the announcements.
I would expect in the next couple of years the first AI-designed drugs in the clinic.
These are two big examples of an AI-driven drug discovery market thats booming, and increasingly, consolidating.
However, there are also plenty of early-stage companies working on more niche applications of the technology.
Despite all the potential though, AI isnt a silver bullet for drug discovery.
Story bySion Geschwindt
Sion is a freelance science and technology reporter, specialising in climate and energy.
